Show simple item record

dc.contributor.authorChen, Fengqian
dc.contributor.authorLiu, Qi
dc.contributor.authorXiong, Yang
dc.contributor.authorXu, Li
dc.date.accessioned2021-07-06T12:17:57Z
dc.date.available2021-07-06T12:17:57Z
dc.date.issued2021-06-23
dc.identifier.urihttp://hdl.handle.net/10713/16125
dc.description.abstractInflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis are highly debilitating. IBDs are associated with the imbalance of inflammatory mediators within the inflamed bowel. Conventional drugs for IBD treatment include anti-inflammatory medications and immune suppressants. However, they suffer from a lack of bioavailability and high dose-induced systemic side effects. Nanoparticle (NP)-derived therapy improves therapeutic efficacy and increases targeting specificity. Recent studies have shown that nanomedicines, based on bowel disease's pathophysiology, are a fast-growing field. NPs can prolong the circulation period and reduce side effects by improving drug encapsulation and targeted delivery. Here, this review summarizes various IBD therapies with a focus on NP-derived applications, whereas their challenges and future perspectives have also been discussed.en_US
dc.description.urihttps://doi.org/10.2147/IJN.S310952en_US
dc.description.urihttp://www.ncbi.nlm.nih.gov/pmc/articles/pmc8236271/en_US
dc.language.isoenen_US
dc.publisherDove Pressen_US
dc.relation.ispartofInternational Journal of Nanomedicineen_US
dc.rights© 2021 Chen et al.en_US
dc.subjectinflammatory bowel diseaseen_US
dc.subjectnanomedicine applicationsen_US
dc.subjectnanoparticlesen_US
dc.subjecttargeted deliveryen_US
dc.titleCurrent Strategies and Potential Prospects of Nanomedicine-Mediated Therapy in Inflammatory Bowel Diseaseen_US
dc.typeArticleen_US
dc.identifier.doi10.2147/IJN.S310952
dc.identifier.pmid34188471
dc.source.volume16
dc.source.beginpage4225
dc.source.endpage4237
dc.source.countryNew Zealand


This item appears in the following Collection(s)

Show simple item record